Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
Status:
Completed
Trial end date:
2017-09-20
Target enrollment:
Participant gender:
Summary
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3
doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1
diabetes mellitus as adjunctive therapy to insulin